Our medical, nursing and allied health clinicians are increasingly involved in research to improve the care of our patients. This is reflected in the breadth of our research publications.
Evolution of Brain Volume Loss Rates in Early Stages of Multiple Sclerosis
Uher, T; Krasensky, J; Malpas, C; Bergsland, N; Dwyer, MG; Havrdova, EK; Vaneckova, M; Horakova, D; Zivadinov, R; Kalincik, T
(2021), Neurol.-Neuroimmunol. Neuroinflammation
High BMI in Youths as a Modifiable Risk Factor for Multiple Sclerosis Weighing Up the Evidence
Kalincik, T; Tremlett, H; Ascherio, A
(2021), Neurology, 1057-1058
Has the Time Come to Revisit Our Standard Measures of Disability Progression in Multiple Sclerosis?
Kalincik, T; Sormani, MP; Tur, C
(2021), Neurology, 12-13
Effects of High- and Low-Efficacy Therapy in Secondary Progressive Multiple Sclerosis
Roos, I; Leray, E; Casey, R; Horakova, D; Havrdova, E; Izquierdo, G; Madueno, SE; Patti, F; Edan, G; Debouverie, M; Pelletier, J; Ozakbas, S; Amato, MP; Clavelou, P; Grammond, P; Boz, C; Buzzard, K; Skibina, O; Ciron, J; Gerlach, O; Grand'Maison, F; Lechner-Scott, J; Malpas, C; Butzkueven, H; Vukusic, S; Kalincik, T
(2021), Neurology, E869-E880
Effect of Disease-Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 Years
Kalincik, T; Diouf, I; Sharmin, S; Malpas, C; Spelman, T; Horakova, D; Havrdova, EK; Trojano, M; Izquierdo, G; Lugaresi, A; Prat, A; Girard, M; Duquette, P; Grammond, P; Jokubaitis, V; Van der Walt, A; Grand'Maison, F; Sola, P; Ferraro, D; Shaygannejad, V; Alroughani, R; Hupperts, R; Terzi, M; Boz, C; Lechner-Scott, J; Pucci, E; Van Pesch, V; Granella, F; Bergamaschi, R; Spitaleri, D; Slee, M; Vucic, S; Ampapa, R; McCombe, P; Ramo-Tello, C; Prevost, J; Olascoaga, J; Cristiano, E; Barnett, M; Saladino, ML; Sanchez-Menoyo, JL; Hodgkinson, S; Rozsa, C; Hughes, S; Moore, F; Shaw, C; Butler, E; Skibina, O; Gray, O; Kermode, A; Csepany, T; Singhal, B; Shuey, N; Piroska, I; Taylor, B; Simo, M; Sirbu, CA; Sas, A; Butzkueven, H
(2021), Neurology, E783-E797
Association Between Cognitive Trajectories and Disability Progression in Patients With Relapsing-Remitting Multiple Sclerosis
Merlo, D; Stankovich, J; Bai, C; Kalincik, T; Zhu, C; Gresle, M; Lechner-Scott, J; Kilpatrick, T; Barnett, M; Taylor, B; Darby, D; Butzkueven, H; Van der Walt, A
(2021), Neurology, E2020-E2031
Comparative effectiveness of rituximab in multiple sclerosis
Kalincik, T; Sormani, MP
(2021), Nat. Rev. Neurol., 3-4
Real-world effectiveness of cladribine for Australian patients with multiple sclerosis: An MSBase registry substudy
Lizak, N; Hodgkinson, S; Butler, E; Lechner-Scott, J; Slee, M; McCombe, PA; Shaw, C; Skibina, O; Vucic, S; Shuey, N; Barnett, MH; Parratt, J; Butzkueven, H; Jack, D; Fabris, J; Kalincik, T
(2021), Mult. Scler. J., 465-474
Prediction of on-treatment disability worsening in RRMS with the MAGNIMS score
Kunchok, A; Lechner-Scott, J; Granella, F; Trojano, M; Alroughani, R; Sola, P; Ferraro, D; Lugaresi, A; Onofrj, M; Ozakbas, S; Izquierdo, G; Grammond, P; Sanchez-Menoyo, JL; Van Wijmeersch, B; Boz, C; Pucci, E; McCombe, P; Grand'Maison, F; Spitaleri, D; Vucic, S; Hupperts, R; Jokubaitis, V; Sormani, MP; Butzkueven, H; Kalincik, T
(2021), Mult. Scler. J., 695-705
Disability outcomes of early cerebellar and brainstem symptoms in multiple sclerosis
Le, M; Malpas, C; Sharmin, S; Horakova, D; Havrdova, E; Trojano, M; Izquierdo, G; Eichau, S; Ozakbas, S; Lugaresi, A; Prat, A; Girard, M; Duquette, P; Larochelle, C; Alroughani, R; Bergamaschi, R; Sola, P; Ferraro, D; Grammond, P; Maison, FG; Terzi, M; Boz, C; Hupperts, R; Butzkueven, H; Pucci, E; Granella, F; Van Pesch, V; Soysal, A; Yamout, BI; Lechner-Scott, J; Spitaleri, DLA; Ampapa, R; Turkoglu, R; Iuliano, G; Ramo-Tello, C; Sanchez-Menoyo, JL; Sidhom, Y; Gouider, R; Shaygannejad, V; Prevost, J; Altintas, A; Fragoso, YD; McCombe, PA; Petersen, T; Slee, M; Barnett, MH; Vucic, S; Van der Walt, A; Kalincik, T
(2021), Mult. Scler. J., 755-766
Clinical outcomes in patients who discontinue natalizumab therapy after 2 years in the Tysabri(R) Observational Program (TOP)
Butzkueven, H; Trojano, M; Kappos, L; Spelman, T; Wiendl, H; Rosales, K; Su, R; Licata, S; Ho, PR; Campbell, N
(2021), Mult. Scler. J., 410-419
Measurement of neurofilaments improves stratification of future disease activity in early multiple sclerosis
Uher, T; Havrdova, EK; Benkert, P; Bergsland, N; Krasensky, J; Srpova, B; Dwyer, M; Tyblova, M; Meier, S; Vaneckova, M; Horakova, D; Zivadinov, R; Leppert, D; Kalincik, T; Kuhle, J
(2021), Mult. Scler. J., 2001-2013
Determinants of therapeutic lag in multiple sclerosis
Roos, I; Leray, E; Frascoli, F; Casey, R; Brown, JWL; Horakova, D; Havrdova, EK; Debouverie, M; Trojano, M; Patti, F; Izquierdo, G; Eichau, S; Edan, G; Prat, A; Girard, M; Duquette, P; Onofrj, M; Lugaresi, A; Grammond, P; Ciron, J; Ruet, A; Ozakbas, S; De Seze, J; Louapre, C; Zephir, H; Sa, MJ; Sola, P; Ferraro, D; Labauge, P; Defer, G; Bergamaschi, R; Lebrun-Frenay, C; Boz, C; Cartechini, E; Moreau, T; Laplaud, D; Lechner-Scott, J; Grand'Maison, F; Gerlach, O; Terzi, M; Granella, F; Alroughani, R; Iuliano, G; Van Pesch, V; Van Wijmeersch, B; La Spitaleri, D; Soysal, A; Berger, E; Prevost, J; Aguera-Morales, E; McCombe, P; Trivino, TC; Clavelou, P; Pelletier, J; Turkoglu, R; Stankoff, B; Gout, O; Thouvenot, E; Heinzlef, O; Sidhom, Y; Gouider, R; Csepany, T; Bourre, B; Al Khedr, A; Casez, O; Cabre, P; Montcuquet, A; Wahab, A; Camdessanche, JP; Maurousset, A; Patry, I; Hankiewicz, K; Pottier, C; Maubeuge, N; Labeyrie, C; Nifle, C; Coles, A; Malpas, CB; Vukusic, S; Butzkueven, H; Kalincik, T
(2021), Mult. Scler. J., 1838-1851
The effectiveness of natalizumab vs fingolimod-A comparison of international registry studies
Andersen, JB; Sharmin, S; Lefort, M; Koch-Henriksen, N; Sellebjerg, F; Sorensen, PS; Christensen, CCH; Rasmussen, PV; Jensen, MB; Frederiksen, JL; Bramow, S; Mathiesen, HK; Schreiber, KI; Horakova, D; Havrdova, EK; Alroughani, R; Izquierdo, G; Eichau, S; Ozakbas, S; Patti, F; Onofrj, M; Lugaresi, A; Terzi, M; Grammond, P; Maison, FG; Yamout, B; Prat, A; Girard, M; Duquette, P; Boz, C; Trojano, M; McCombe, P; Slee, M; Lechner-Scott, J; Turkoglu, R; Sola, P; Ferraro, D; Granella, F; Shaygannejad, V; Prevost, J; Skibina, O; Solaro, C; Karabudak, R; Wijmeersch, BV; Csepany, T; Spitaleri, D; Vucic, S; Casey, R; Debouverie, M; Edan, G; Ciron, J; Ruet, A; Seze, JD; Maillart, E; Zephir, H; Labauge, P; Defer, G; Lebrun, C; Moreau, T; Berger, E; Clavelou, P; Pelletier, J; Stankoff, B; Gout, O; Thouvenot, E; Heinzlef, O; Al-Khedr, A; Bourre, B; Casez, O; Cabre, P; Montcuquet, A; Wahab, A; Camdessanche, JP; Marousset, A; Patry, I; Hankiewicz, K; Pottier, C; Maubeuge, N; Labeyrie, C; Nifle, C; Leray, E; Laplaud, DA; Butzkueven, H; Kalincik, T; Vukusic, S; Magyari, M
(2021), Mult. Scler. Relat. Disord.
Fast and safe: Optimising multiple sclerosis infusions during COVID-19 pandemic
Rath, L; Bui, MV; Ellis, J; Carey, J; Baker, J; Taylor, L; Fernando, H; Taylor, N; Savage, P; Richards, J; Zhong, M; Kalincik, T; Skibina, O; Wesselingh, R; Nguyen, A; Monif, M; Butzkueven, H; van der Walt, A
(2021), Mult. Scler. Relat. Disord.
Long-term outcomes in patients presenting with optic neuritis: Analyses of the MSBase registry
Kenney, R; Liu, ML; Patil, S; Alroughani, R; Ampapa, R; Bergamaschi, R; Boz, C; Butzkueven, H; Gomez, JC; Cartechini, E; Madueno, SE; Ferraro, D; Grand-Maison, F; Granella, F; Horakova, D; Ayuso, GI; Kalincik, T; Preiningerova, JL; Lugaresi, A; Onofrj, M; Ozakbas, S; Patti, F; Sola, P; Soysal, A; Spitaleri, DLA; Terzi, M; Turkoglu, R; van Pesch, V; Saidha, S; Thorpe, LE; Galetta, SL; Balcer, LJ; Kister, I; Spelman, T
(2021), J. Neurol. Sci.
Effect of lateral therapy switches to oral moderate-efficacy drugs in multiple sclerosis: a nationwide cohort study
Buron, MD; Kalincik, T; Sellebjerg, F; Sorensen, PS; Magyari, M
(2021), J. Neurol. Neurosurg. Psychiatry, 556-562
Longitudinal machine learning modeling of MS patient trajectories improves predictions of disability progression
De Brouwer, E; Becker, T; Moreau, Y; Havrdova, EK; Trojano, M; Eichau, S; Ozakbas, S; Onofrj, M; Grammond, P; Kuhle, J; Kappos, L; Sola, P; Cartechini, E; Lechner-Scott, J; Alroughani, R; Gerlach, O; Kalincik, T; Granella, F; Grand'Maison, F; Bergamaschi, R; Sa, MJ; Van Wijmeersch, B; Soysal, A; Sanchez-Menoyo, JL; Solaro, C; Boz, C; Iuliano, G; Buzzard, K; Aguera-Morales, E; Terzi, M; Trivio, TC; Spitaleri, D; Van Pesch, V; Shaygannejad, V; Moore, F; Oreja-Guevara, C; Maimone, D; Gouider, R; Csepany, T; Ramo-Tello, C; Peeters, L
(2021), Comput. Meth. Programs Biomed.
Utilization of Multiple Sclerosis Therapies in the Middle East Over a Decade: 2009-2018
Moradi, N; Sharmin, S; Malpas, C; Ozakbas, S; Shaygannejad, V; Terzi, M; Boz, C; Yamout, B; Turkoglu, R; Karabudak, R; Hamdy, S; Soysal, A; Altintas, A; Inshasi, J; Al-Harbi, T; Alroughani, R; Kalincik, T
(2021), CNS Drugs, 1097-1106
Predicting Infection Risk in Multiple Sclerosis Patients Treated with Ocrelizumab: A Retrospective Cohort Study
Seery, N; Sharmin, S; Li, V; Nguyen, AL; Meaton, C; Atvars, R; Taylor, N; Tunnell, K; Carey, J; Marriott, MP; Buzzard, KA; Roos, I; Dwyer, C; Baker, J; Taylor, L; Spriggs, K; Kilpatrick, TJ; Kalincik, T; Monif, M
(2021), CNS Drugs, 907-918
Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International Cohorts
Sharmin, S; Lefort, M; Andersen, JB; Leray, E; Horakova, D; Havrdova, EK; Alroughani, R; Izquierdo, G; Ozakbas, S; Patti, F; Onofrj, M; Lugaresi, A; Terzi, M; Grammond, P; Grand'Maison, F; Yamout, B; Prat, A; Girard, M; Duquette, P; Boz, C; Trojano, M; McCombe, P; Slee, M; Lechner-Scott, J; Turkoglu, R; Sola, P; Ferraro, D; Granella, F; Prevost, J; Maimone, D; Skibina, O; Buzzard, K; Van der Walt, A; Van Wijmeersch, B; Csepany, T; Spitaleri, D; Vucic, S; Casey, R; Debouverie, M; Edan, G; Ciron, J; Ruet, A; De Seze, J; Maillart, E; Zephir, H; Labauge, P; Defer, G; Lebrun-Frenay, C; Moreau, T; Berger, E; Clavelou, P; Pelletier, J; Stankoff, B; Gout, O; Thouvenot, E; Heinzlef, O; Al-Khedr, A; Bourre, B; Casez, O; Cabre, P; Montcuquet, A; Wahab, A; Camdessanche, JP; Maurousset, A; Patry, I; Hankiewicz, K; Pottier, C; Maubeuge, N; Labeyrie, C; Nifle, C; Laplaud, D; Koch-Henriksen, N; Sellebjerg, FT; Soerensen, PS; Pfleger, CC; Rasmussen, PV; Jensen, MB; Frederiksen, JL; Bramow, S; Mathiesen, HK; Schreiber, KI; Magyari, M; Vukusic, S; Butzkueven, H; Kalincik, T
(2021), CNS Drugs, 1217-1232
Adverse events related to antiepileptic drugs
Dang, YL; Foster, E; Lloyd, M; Rayner, G; Rychkova, M; Ali, R; Carney, PW; Velakoulis, D; Winton-Brown, TT; Kalincik, T; Perucca, P; O'Brien, TJ; Kwan, P; Malpas, CB
(2021), Epilepsy Behav.
Development and Pilot Implementation of TACTICS VR: A Virtual Reality-Based Stroke Management Workflow Training Application and Training Framework
Hood, RJ; Maltby, S; Keynes, A; Kluge, MG; Nalivaiko, E; Ryan, A; Cox, M; Parsons, MW; Paul, CL; Garcia-Esperon, C; Spratt, NJ; Levi, CR; Walker, FR
(2021), Front. Neurol.
Utility of Severity-Based Prehospital Triage for Endovascular Thrombectomy ACT-FAST Validation Study
Zhao, H; Smith, K; Bernard, S; Stephenson, M; Ma, H; Chandra, RV; Phan, T; Bladin, CF; Churilov, L; Crompton, D; Dewey, HM; Wijeratne, T; Cloud, G; Thijs, V; Kleinig, TJ; Ng, JL; Williams, C; Alemseged, F; Ng, F; Mitchell, PJ; Parsons, MW; Yassi, N; Davis, SM; Campbell, BCV
(2021), Stroke, 70-79
Endovascular Treatment Effect Diminishes With Increasing Thrombus Perviousness Pooled Data From 7 Trials on Acute Ischemic Stroke
Kappelhof, M; Tolhuisen, ML; Treurniet, KM; Dutra, BG; Alves, H; Zhang, G; Brown, S; Muir, KW; Davalos, A; Roos, YBWEM; Saver, JL; Demchuk, AM; Jovin, TG; Bracard, S; Campbell, BCV; van der Lugt, A; Guillemin, F; White, P; Hill, MD; Dippel, DWJ; Mitchell, PJ; Goyal, M; Marquering, HA; Majoie, CBLM
(2021), Stroke, 3633-3641
Prediction of Outcome and Endovascular Treatment Benefit Validation and Update of the MR PREDICTS Decision Tool
Venema, E; Roozenbeek, B; Mulder, MJHL; Brown, S; Majoie, CBLM; Steyerberg, EW; Demchuk, AM; Muir, KW; Davalos, A; Mitchell, PJ; Bracard, S; Berkhemer, OA; Nijeholt, GJLA; Van Oostenbrugge, RJ; Roos, YBWEM; Van Zwam, WH; Van der Lugt, A; Hill, MD; White, P; Campbell, BCV; Guillemin, F; Saver, JL; Jovin, TG; Goyal, M; Dippel, DWJ; Lingsma, HF
(2021), Stroke, 2764-2772
Optimal Tissue Reperfusion Estimation by Computed Tomography Perfusion Post-Thrombectomy in Acute Ischemic Stroke
Tan, ZF; Parsons, M; Bivard, A; Sharma, G; Mitchell, P; Dowling, R; Bush, S; Xu, AD; Yan, B
(2021), Stroke, E760-E763
Computed Tomography Perfusion-Based Machine Learning Model Better Predicts Follow-Up Infarction in Patients With Acute Ischemic Stroke
Kuang, HL; Qiu, W; Boers, AM; Brown, S; Muir, K; Majoie, CBLM; Dippel, DWJ; White, P; Epstein, J; Mitchell, PJ; Davalos, A; Bracard, S; Campbell, B; Saver, JL; Jovin, TG; Rubiera, M; Khaw, AV; Shankar, JJ; Fainardi, E; Hill, MD; Demchuk, AM; Goyal, M; Menon, BK
(2021), Stroke, 223-231
Comparing the Prognostic Impact of Age and Baseline National Institutes of Health Stroke Scale in Acute Stroke due to Large Vessel Occlusion
Ospel, JM; Brown, S; Kappelhof, M; van Zwam, W; Jovin, T; Roy, D; Campbell, BCV; Mitchell, P; Roos, Y; Guillemin, F; Buck, B; Muir, K; Bracard, S; White, P; de Rochemont, RD; Goyal, M
(2021), Stroke, 2839-2845
Cerebral Edema in Patients With Large Hemispheric Infarct Undergoing Reperfusion Treatment A HERMES Meta-Analysis
Ng, FC; Yassi, N; Sharma, G; Brown, SB; Goyal, M; Majoie, CBLM; Jovin, TG; Hill, MD; Muir, KW; Saver, JL; Guillemin, F; Demchuk, AM; Menon, BK; San Roman, L; Liebeskind, DS; White, P; Dippel, DWJ; Davalos, A; Bracard, S; Mitchell, PJ; Wald, MJ; Davis, SM; Sheth, KN; Kimberly, WT; Campbell, BCV
(2021), Stroke, 3450-3458